Compare GSK plc (GSK) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Paychex, Inc. — how do they compare? GSK plc trades at $52.4 (market cap $101.34B), while Paychex, Inc. trades at $112.73 (market cap $39.12B). The key difference: GSK plc is far larger — about 2.6× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.33%). Which is the better fit depends on your goals.
| GSK | PAYX | |
|---|---|---|
Market Cap | $101.34B | $39.12B |
Sector | Health | Industrials |
52-Week High | $61.18 | $147.99 |
52-Week Low | $36.20 | $85.57 |
Enterprise Value | $121.95B | $42.60B |
Dividend Yield | 3.49% | 4.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Paychex (PAYX) trades at $109.52, down 1.11% today but near the consensus price target of $110. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating estimates. Technical indicators are bullish on moving averages while oscillators remain neutral. Recent news highlights AI expansion and strong small business job growth, supporting the positive outlook.
PAYX presents a balanced investment case with robust profitability (27% net margin) and dividend appeal, though valuation multiples appear elevated. Key risks include macroeconomic sensitivity to small business hiring and competitive pressures. Analyst sentiment is mixed with 63% hold ratings, suggesting cautious optimism amid current price levels near fair value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
